Experience with febuxostat in a patient with severe disabling gout
Gout is a chronic disease that frequently leads to disability if urate-lowering therapy is inefficient. The paper presents the positive experience with febuxostat, a novel non-purine xanthine oxidase inhibitor, in a young patient with disabling chronic tophaceous gout. Twelve-month therapy with dail...
Saved in:
Main Authors: | M. S. Eliseev, R. U. Shayakhmetova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2017-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/779 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The ‘FebBenz’ approach for severe difficult-to-treat gout
by: Enrique Calvo-Aranda, et al.
Published: (2025-05-01) -
Battle of the strategies: diet versus drug therapy for gout
by: O. V. Zhelyabina, et al.
Published: (2024-06-01) -
Urate-lowering therapy for heart failure
by: O. V. Zhelyabina, et al.
Published: (2019-09-01) -
Febuxostat in the therapy of gout: from theory to practice
by: E. V. Ilyinykh, et al.
Published: (2018-01-01) -
UPDATED EULAR GUIDELINES FOR THE MANAGEMENT OF GOUT. COMMENTS ON CERTAIN ITEMS
by: M. S. Eliseev
Published: (2018-01-01)